This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

Subject Index

Subject Index Volume 2

A-289099
antitumor activity, 227

Abasic site repair
blockade

enhances BCNU antitumor effect, in vivo and in vitro colon cancer cells, 1061

Adducts
Adriamycin

DNA sequence specificity, 661

Adenoviral Vector
construction and characterization of Ad-sCE2

sensitization of osteosarcoma to CPT-11, 765

p53

differential effects on radiosensitivity, epidermal and lung cancer cells, 1223

Adozelesin
compared with bizelesin

different cellular responses, colon cancer cells, 651

DNA-damaging response

role of S phase and DNA replication forks, 41

Adriamycin
activation by formaldehyde-releasing prodrug

AN-9

DNA sequence specificity of adriamycin adducts, 661

HMTA

cultured IMR-32 neuroblastoma cells, 189

AIRK Kinases
oncogenic role in tumorigenesis

aurora-2 (minireview), 589

AK-5 Rat Histiocytic Tumor Cells
effect of phycocyanin, 1165

Akt
novel strategy to inhibit activation, DPI analogues, 389

phosphorylation

celecoxib with emodin, cultured rat C611B ChC and WBneu cells, 265

inhibited by perifosine, prostate cancer cells, 1093

and radiotherapy resistance, breast cancer cells, 353

Alchemix
novel agent maintains potent cytotoxicity against drug-resistant ovarian cancer, in vitro and in mice, 607

Alginate Solution
intratumoral injection

reduces virus dissemination, 1233

Alkaloid
naamidine A

causes G₁ cell cycle arrest, epidermoid cancer cells, 747

Alkylphospholipids
perifosine

inhibits protein kinase B/Akt phosphorylation and activation, prostate cancer cells, 1093

Allicin (diallyl thiosulfinate)
tumor growth inhibition

in situ allicin generation with targeted alliinase delivery, 1295

Amifostine
effect on p53-mediated apoptosis, leukemia cells, 893

Amino Acids
alignment of sequences

human and monkey MRP1, 307

substituted with cysteine

novel PAI-1 mutations, 19

2-[4-Amino-3-methylphenyl]-5-fluoro-benzothiazole (5F-203)
induction of CYP1A1, multiple cell lines, 1265

Androgen Receptor Antogonist Activity
vitamin E derivative PMCol, prostate cancer cells, 797

Angiogenesis
inhibition

differential effects of bortezomib, prostate cancer in vitro and in xenografts, 835

E1A gene, Ewing's sarcoma animal model, mouse xenografts, 1313

endostatin, 845

piroxicam with cisplatin chemotherapy, urinary bladder cancer, canine model, 183

SU5416, prostate cancer, mice, 611

Trx-1 inhibitors PX-12 and pleurotin, 235

regulation by COX-2, pancreatic tumors, 1

Angiotensin II Receptor Blockers (ARB)
inhibits cell proliferation of prostate cancer, in vivo and in vitro, 1139

Ansamycins
geldanamycin derivative 17AAG

pharmacological audit trail (commentary), 131

physicochemical characteristics and Hsp90 binding affinity, prostate epithelial cells, 123

Anthracycline Resistance
cloning and characterization of MRP1 from cynomolgus monkey

comparison with human, 307

Anthracyclines
cytotoxicity

synthetic taxane-based reversal agents, 1195

doxorubicin

with tetrathiomolybdate, breast cancer, mice, 617

Antiestrogens
derivatives

BCRP-mediated drug resistance, 105

Antimitotic Compounds
indolyloxazoline derivative A-289099, 227

Antioxidants
MnSOD

tumor suppression, pancreatic cancer, 361

Antisense Oligonucleotide
Morpholino

inhibition of laminin-8, glioma cells, 985

p21

breast cancer, 773

Apoptosis
BCR-ABL-positive cells

SCH66336 with imatinib, 219

cultured rat C611B ChC and WBneu cells

celecoxib with emodin, 265

DNA damage-induced

enhanced by Chk1 small interfering RNA, 543

indolyloxazoline derivative A-289099, 227

induction

antisense oligodeoxynucleotide to p21, breast cancer, 773

differential effects of bortezomib, prostate cancer in vitro and in xenografts, 835

Dox and Taxol, NSCLC cells, 641

DPI analogues prevent Akt translocation, 389

exisulind with docetaxel treatment, non-small cell lung cancer, rats, 479

farnesyl transferase inhibitors, myeloma tumor cells, 563

flavopiridol

and bryostatin 1 combination, leukemia cells, 83

following docetaxel, gastric cancer cells, in vitro and mouse xenografts, 549

glioma cell lines, 139

lung cancer cells, 73

GrB/VEGF₁₂₁, a novel vascular-targeting fusion construct, 949

IL-4 cytotoxin, xenograft prostate tumor models, 245

LAQ824 with epothilone B, gemcitabine, taxotere, or trastuzumab, breast cancer cells, 971

in normal T cells with arsenic trioxide, 711

novel aerosolized Vitamin E analog -TEA, mice, 437

phycocyanin, rat AK-5 tumor line cells, 1165

piroxicam with cisplatin chemotherapy, urinary bladder cancer, canine model, 183

retinoid synergists with Am80, leukemia cells, 49

rituximab with paclitaxel, non-Hodgkin's lymphoma B cells, 1183

RRM, Z-FA-fmk, 255

tetrathiomolybdate with doxorubicin, breast cancer, mice, 617

triptolide, solid tumors, 65

Vinca alkaloids suppress spindle microtubule dynamics, 427

manipulation

strategies for tumor chemosensitization (minireview), 805

mechanisms

and clinical approaches to induce (minireview), 573

p53-mediated

effect of amifostine, leukemia cells, 893

prostate cancer-specific

SU5416, mice, 611

TRAIL-induced

and curcumin combination, prostate cancer cells, 95

glycogen synthase kinase-3ß suppression, prostate cancer cells, 1215

with histone deacetylase inhibitors, leukemia cells, 1273

Arsenic Trioxide
apoptosis induction in normal T cells, 711

caspase-dependent and -independent death pathways, myeloma cells, 1155

interacts with MDA-7 to promote cell death, renal cancer cells, 623

Aspirin
stabilizes ß-catenin phosphorylation, colorectal cancer cells, 509

Atorvastatin
effect on Rho proteins and metastasis of melanoma cells in vitro, 941

ATP-Binding Cassette (ABC) Transporters
overexpression

synthetic taxane-based reversal agents, 1195

role in cancer and chemotherapy (review), 685

Aurora2 Kinase
homology modeling and docking simulations, 283

oncogenic role in tumorigenesis (minireview), 589

B

Bax Protein
flavopiridol-induced apoptosis, glioma cell lines, 139

Bcl-2
expression

phycocyanin-mediated apoptosis in rat AK-5 tumor cells, 1165

phosphorylation

Dox and Taxol induced apoptosis, NSCLC cells, 641

protein

down-regulation with G3139, prostate cancer cells, 1031

flavopiridol-induced apoptosis, glioma cell lines, 139

role in arsenic trioxide-induced apoptosis, 711

Bcl-xL Expression
rituximab and paclitaxel, non-Hodgkin's lymphoma B cells, 1183

BCNU [1,3-bis-(2-chloroethyl)-1-nitrosourea]
with methoxyamine and O⁶-BG, in vivo and in vitro colon cancer cells, 1061

BCR/ABL Activated Genes
known and novel, chronic myelogenous leukemia cells, 173

Benzothiazoles
5F-203

induction of CYP1A1, multiple cell lines, 1265

Binarization
gene microarray data

based on multiplicative model for expression up-regulation, 679

1,3-Bis-(2-chloroethyl)-1-nitrosourea (BCNU)
with O⁶-BG

MGMT-P140K-transduced hematopoietic cells allow dose intensification, murine model, 1321

with methoxyamine, in vivo and in vitro colon cancer cells, 1061

Bis-CpG Motif
mechanism of action of G3139, prostate cancer cells, 1031

Bisperoxovanadium (bpV) Analogues
antineoplastic activity, multiple cell lines in vivo and in vitro, 1053

Bizelesin
compared with adozelesin

induce different cellular responses, colon cancer cells, 651

Bladder Cancer
piroxicam with cisplatin chemotherapy, urinary, canine model, 183

Bladder Cancer Cells
SW780

novel oncolytic adenovirus OV798, 1003

T24

treated with three HDAC inhibitors, 151

TSU

antitumor effects of triptolide, 65

Bone Marrow Transplantation
MGMT-P140K-transduced hematopoietic cells

protection against intensive BG/BCNU antitumor treatment, murine model, 1321

Bortezomib
prostate cancer, in vitro and in xenografts, 835

Brain Tumors
fusion protein therapy

receptor density measurements, 783

magnetic resonance spectroscopy (minireview), 497

molecular profiles for RG2 rat glioma cells, 1129

Breast Cancer
radiotherapy resistance

role of PI-3K/Akt pathway, 353

SU(Z)12 upregulation in human tumors, 113

Breast Cancer Cells
BT474, MCF7, MDA453, MDA468, SKBR3, ZR75B

radiosensitization by trastuzumab, 1113

BT474, MCF7, MDA-MB-231, SKBR-3

mechanism of action of Kahalalide F, 863

BT474, SKBR-3

novel histone deacetylase inhibitor LAQ824, 971

MCF-7

17AAG characteristics and Hsp90 binding affinity, 123

antiproliferative activity of selected isothiocyanates, 1045

DPI analogues prevent Akt translocation, 389

novel xenograft model for human FAP expression, 729

PXD101, a novel HDAC inhibitor, 721

role of PKC , 273

Trx-1 inhibitors PX-12 and pleurotin, 235

MCF7, MDA435/LCC6

synthetic taxane-based reversal agents, 1195

MCF7, T47D

antisense oligodeoxynucleotide to p21, 773

MDA

treated with three HDAC inhibitors, 151

MDA231, MDA468, T47D

P450 potentiates mitomycin C, in vitro and xenograft model, 901

MDA-435

antitumor effects of triptolide, 65

MDA-MB-231

role of PKC , 273

MDA-MB-435, MX-1

SU11248 alone and with docetaxel, 5-fluorouracil, or doxorubicin, xenograft study, 1011

MDA-MB-468

SFK dependency of STAT3 and FAK phosphoepitopes, 461

SUM149

tetrathiomolybdate with doxorubicin, mice, 617

Breast Cancer Resistance Protein (BCRP)
drug resistance

estrogen antagonists, agonists, and derivatives, 105

tamoxifen derivatives, 105

overexpression

synthetic taxane-based reversal agents, 1195

C

C-1027
DNA-damaging response

role of S phase and DNA replication forks, 41

Camptothecin (CPT)
conjugates

antitumor activity against human tumor xenografts, mice, 29

DNA-damaging response

role of S phase and DNA replication forks, 41

Camptothecin Derivative CPT-11
molecular analysis and docking studies

development of prodrugs activated by specific carboxylesterases, 765

sensitization of osteosarcoma to CPT-11, 765

Cancer. See also Specific Cells and Types
classification

gene expression microarray data, patient database, 317

role of ATP-binding cassette transporters (review), 685

role of iNOS (minireview), 815

therapeutics

-Fetoprotein growth inhibitory peptides (review), 1243

mathematical models of tumor-host interface, 919

Carboplatin
cytotoxicity enhanced with O⁶-BG, head and neck cancer cell lines, 633

Carboxylesterase
specific analogues

camptothecin prodrug activation prediction, 1171

Carboxylesterase-2 (CE2)
sensitization of osteosarcoma to CPT-11, 765

Carcinoembryonic Antigen (CEA)
transcriptional regulatory elements

oncolytic adenovirus OV798, a novel CEA promoter and enhancer, colorectal cancer, 1003

Caspase
activation

apoptosis by curcumin and TRAIL combination, 95

arsenic trioxide-induced apoptosis, 711

flavopiridol-induced apoptosis, glioma cell lines, 139

glycogen synthase kinase-3ß suppression and TRAIL-induced apoptosis, prostate cancer cells, 1215

inhibition

Z-FA-fmk, 255

phycocyanin-mediated apoptosis in rat AK-5 tumor cells, 1165

role in arsenic trioxide-mediated cell death, myeloma cells, 1155

sulindac metabolite induction of ß-catenin protein degradation, colon cancer cells, 885

TRAIL with histone deacetylase inhibitors, leukemia cells, 1273

Caspase-3
activation

celecoxib with emodin, 265

Caspase-9
activation

celecoxib with emodin, 265

ß-Catenin
protein

degradation by sulindac metabolites, colon cancer cells, 885

TCF/ß-catenin complexes

SU(Z)12 upregulation in human tumors, 113

ß-Catenin/T-Cell Transcription Factor Signaling
reduction by aspirin and indomethacin, stabilization of phosphorylated ß-catenin, 509

Cathepsins
RRM-induced apoptosis, Z-FA-fmk, 255

CD80
alternative to green fluorescent protein marker, 911

costimulatory molecules added to plasmid-based DNA vaccine encoding rat neu, in mice, 995

CD86
costimulatory molecules added to plasmid-based DNA vaccine encoding rat neu, in mice, 995

CD137L
costimulatory molecules added to plasmid-based DNA vaccine encoding rat neu, in mice, 995

Cdc25A
antineoplastic activity of bisperoxovanadium analogues, multiple cell lines in vivo and in vitro, 1053

Cervical Cancer Cells
HeLa

telomerase inhibition by siRNA, 209

HeLa S3

Chk1 small interfering RNA, 543

Chemosensitivity
relevance network with gene expression profile, human hepatoma cells, 199

Chemosensitization
tumors

apoptosis manipulation strategies (minireview), 805

Chemotherapy
role of ATP-binding cassette transporters (review), 685

Chk1 Small Interfering RNA
role in apoptosis, cell cycle progression, and response to DNA-damaging agents, somatic cells, 543

Chloroethylaminoanthraquinone
Alchemix

novel agent maintains potent cytotoxicity, drug-resistant ovarian cancer, in vitro and in mice, 607

Cholangiocarcinoma
celecoxib with emodin, cultured rat cells, 265

CHOP Chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone)
with genistein, large cell lymphoma xenografts, 1361

CI-994 or N-acetyldinaline [4-(acetylamino)-N-(2-amino-phenyl) benzamide]
HDAC inhibition, colon cancer cells, 401

Cisplatin
cytotoxicity enhanced with O⁶-BG

head and neck cancer cell lines, 633

p53-independent response, mouse salivary tumors, 165

resistance

novel agent Alchemix maintains potent cytotoxicity, ovarian cancer, in vitro and in mice, 607

oligosaccharide changes in 5ß1 integrin, squamous cell carcinoma cell line, 1207

with CEP-6800

chemopotentiation, mouse xenografts, 371

with piroxicam

urinary bladder cancer, canine model, 183

with SU11248

small cell lung cancer, mice, 471

9-cis-retinoic Acid
with VD₃

hTERT transcription, prostate cancer cells, 739

Classification
tumors

gene expression microarray data, patient database, 317

CNS Cancer Cells
SF295, SNB75

antineoplastic activity of bisperoxovanadium analogues, 1053

Colcemid
resistance

role of - and ß-tubulin alterations, 597

Colon Cancer
antitumor activity of ER-37328

murine orthotopic transplantation model, 59

SU(Z)12 upregulation in human tumors, 113

Colon Cancer Cells
Colo205

SFK dependency of STAT3 and FAK phosphoepitopes, 461

triptolide derivative PG490-88, in vitro and xenograft model, solid tumors, 855

Colo-320DM, LoVo, RKO, SW620

novel oncolytic adenovirus OV798, 1003

HCT8

HDAC inhibition by CI-994, 401

HCT15

telomerase inhibition by siRNA, 209

HCT15, HCT116, HT29, SW480

sulindac induction of ß-catenin protein degradation, 885

HCT116

BCNU antitumor effect, 1061

different cellular responses to adozelesin and bizelesin, 651

novel DNA-dependent protein kinase inhibitors, 1257

p53 activation biomarker MIC-1, 1023

HCT116, HT29

PXD101, a novel HDAC inhibitor, 721

HCT116, SW620

antineoplastic activity of bisperoxovanadium analogues, 1053

HT-29

antiproliferative activity of selected isothiocyanates, 1045

camptothecin HPMA copolymers, 29

chemopotentiating ability of CEP-6800, mouse xenografts, 371

SFK dependency of STAT3 and FAK phosphoepitopes, 461

Trx-1 inhibitors PX-12 and pleurotin, 235

LoVo

chemopotentiating ability of CEP-6800, mouse xenografts, 371

Colorectal Cancer
aspirin and indomethacin stabilize ß-catenin phosphorylation, 509

CYP1B1 expression relative to normal colon, 527

Colorectal Cancer Cells
HT-29

DPI analogues prevent Akt translocation, 389

NCl-HT-29

SFK dependency of STAT3 and FAK phosphoepitopes, 461

Combination Treatment
adenoviral-mediated p16 gene transfer with ionizing radiation, nasopharyngeal cancer cells, 961

BG and BCNU dose intensification, murine model, 1321

bryostatin 1 and flavopiridol, leukemia cells, 83

celecoxib with emodin, cultured rat cholangiocarcinoma, 265

chemopotentiating ability of CEP-6800 with temozolomide, irinotecan, and cisplatin, 371

CHOP chemotherapy and genistein, large cell lymphoma xenografts, 1361

docetaxel

and exisulind, non-small cell lung cancer, rats, 479

followed by flavopiridol, gastric cancer cells, in vitro and mouse xenografts, 549

imatinib, leukemia (commentary), 225

LAQ824 with epothilone B, gemcitabine, taxotere, or trastuzumab, breast cancer cells, 971

MDA-7 with arsenic trioxide, renal cancer cells, 623

methoxyamine with BCNU and O⁶-BG, in vivo and in vitro colon cancer cells, 1061

O⁶-BG with cisplatin and with carboplatin, head and neck cancer cell lines, 633

piroxicam with cisplatin chemotherapy, urinary bladder cancer, canine model, 183

rituximab and paclitaxel, non-Hodgkin's lymphoma B cells, 1183

SCH66336 with imatinib against BCR-ABL-positive cells, leukemia, 219

sensitivity to Ad-sCE2 and CPT-11, osteosarcoma, 765

SU11248

with cisplatin, small cell lung cancer, mice, 471

with docetaxel, 5-fluorouracil, or doxorubicin, in breast cancer xenografts, 1011

tetrathiomolybdate with doxorubicin, breast cancer, mice, 617

TRAIL

and curcumin, prostate cancer cells, 95

with histone deacetylase inhibitors, leukemia cells, 1273

triptolide derivative PG490-88 with CPT-11, in vitro and xenograft model, solid tumors, 855

VD₃ with 9-cis-retinoic acid, prostate cancer cells, 739

CPT-11 (Irinotecan)
molecular analysis and docking studies

development of prodrugs activated by specific carboxylesterases, 1171

prodrug osteosarcoma therapy, 765

with CEP-6800

chemopotentiation, mouse xenografts, 371

with triptolide derivative PG490-88, in vitro and xenograft model, solid tumors, 855

Curcumin
apoptosis induction

with TRAIL, prostate cancer cells, 95

Cyclin-dependent Kinase (CDK)
inhibitor flavopiridol

apoptosis induction, leukemia cells, 83

Cyclooxygenase Inhibitor
piroxicam

with cisplatin chemotherapy, 183

Cyclooxygenase-2 (COX-2)
inhibitor

celecoxib with emodin, cultured rat cells, 265

pancreatic tumors

involvement in angiogenesis and tumor growth, 1

Cyclophosphamide
CHOP chemotherapy with genistein, large cell lymphoma xenografts, 1361

Cyclopropylpyrroloindole Drugs
adozelesin and bizelesin

induce different cellular responses, colon cancer cells, 651

CYP1A1
induction

5F-203, multiple cell lines, 1265

Cysteine
amino acid replacement with

extended PAI-1 half-life, 19

Cytochrome c
release from mitochondria

apoptosis by curcumin and TRAIL combination, 95

Cytochrome P450 1B1 (CYP1B1)
expression in colorectal adenocarcinomas relative to normal colon, 527

Cytokine TNF-
promoter in experimental skin tumors, mice, 445

Cytosine Arabinoside (AraC)
with SCH66336

BCR-ABL-positive cells, 219

Cytotoxic Drugs
limitations revealed by mathematical models, 919

D

Dacarbazine
melanoma cell resistance

IL-8 and VEGF up-regulation, 753

Daunorubicin (DNR)
with SCH66336, BCR-ABL-positive cells, 219

D-3-deoxy-phosphatidyl-myo-inositol (DPI) Analogues
novel growth inhibitory agents

inhibit Akt activation, 389

Diallyl Thiosulfinate (allicin)
tumor growth inhibition

in situ allicin generation with targeted alliinase delivery, 1295

Diazeniumdiolates
JS-K

novel antineoplastic agent, 409

Dihydrofolate Reductase (DHFR)
mRNA expression of E2F transcription factors, osteosarcoma, 535

1,25-Dihydroxyvitamin D₃ (VD₃)
with 9-cis-retinoic acid

hTERT transcription, prostate cancer cells, 739

Discodermolide
microtubule dynamics, lung cancer cells, 1303

DNA Repair
novel DNA-dependent protein kinase inhibitors, colon cancer cells, 1257

suppression

radiosensitivity, epidermal and lung cancer cells, 1223

DNA Vaccines
plasmid-based encoding rat neu

alone or in combination with plasmids encoding CD80, CD86, CD137L, in mice, 995

Docetaxel
followed by flavopiridol, gastric cancer cells, in vitro and mouse xenografts, 549

and paclitaxel compared with novel analogue MAC-321, multiple tumor cell lines in vitro and in vivo, 873

with exisulind, non-small cell lung cancer, rats, 479

with SU11248, breast cancer xenografts, 1011

Docking
simulations

aurora2 kinase, 283

studies

development of camptothecin prodrugs activated by specific carboxylesterases, 1171

Dominant Negative Signal Transducer and Activator of Transcription 2 (dnSTAT2)
IFN- signaling suppression

novel in vitro model, 453

Dox
induced apoptosis, NSCLC cells, 641

Doxorubicin
CHOP chemotherapy with genistein, large cell lymphoma xenografts, 1361

-resistant cell lines

novel agent Alchemix maintains potent cytotoxicity, ovarian cancer, in vitro and in mice, 607

with SU11248, breast cancer xenografts, 1011

with tetrathiomolybdate, breast cancer, mice, 617

Drug Combinations. See also Combination Treatment
preclinical models (meeting report), 929

Drug Development
RNA interference to advance (commentary), 217

DT-diaphorase
overexpression

mitomycin C sensitivity, breast cancer cells, in vitro and xenograft model, 901

E

E1A Gene Therapy
angiogenesis inhibitiion, Ewing's sarcoma cells, mouse xenografts, 1313

E2F Transcription Factors
E2F1

flavopiridol-induced apoptosis, lung cancer cells, 73

mRNA expression, osteosarcoma, 535

Endometrial Cancer Cells
Hec-1B, Ishikawa, and ECC-1

rapamycin inhibits telomerase, 789

Endostatin
anti-angiogenic activity

independent of HIF-1/VEGF pathway, 845

Epidermal Cancer Cells
HaCaT

antiproliferative activity of selected isothiocyanates, 1045

Epidermal Growth Factor Receptor (EGFR)
effect of tyrosine kinase inhibitor ZD1839 (Iressa)

murine hepatocellular carcinoma, 557

squamous cancer cells, 345

expression on brain tumors and normal brain tissues for available fusion proteins, 783

Epidermoid Cancer Cells
A431

naamidin A causes G₁ cell cycle arrest, 747

p53 and radiosensitivity, 1223

telomerase inhibition by siRNA, 209

Epothilone B
microtubule dynamics

compared with discodermolide, lung cancer cells, 1303

with LAQ824, breast cancer cells, 971

Epstein-Barr virus-based Replicon
mouse embryonal fibroblasts

chemical synthetic lethality screen, 1121

ER-37328
colon cancer treatment

murine Colon 38 orthotopic transplantation model, 59

Estrogen
antagonists, agonists, and derivatives

BCRP-mediated drug resistance, 105

7-ethyl-10-[4-(1-piperidono)-1-piperidino]carbonyloxycamptothecin (CPT-11)
molecular analysis and docking studies

development of prodrugs activated by specific carboxylesterases, 1171

Etoposide (VP16)
with SCH66336

BCR-ABL-positive cells, 219

Ewing's Sarcoma Cells
A4573, RD, SK-ES, TC71

E1A gene therapy, mouse xenografts, 1313

Exisulind
alone and with docetaxel

non-small cell lung cancer, rats, 479

Extracellular Signal-regulated Kinase (ERK)
effect of naamidine A, epidermoid cancer cells, 747

F

5F-203 (2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole)
induction of CYP1A1, multiple cell lines, 1265

¹⁹F Magnetic Resonance Spectroscopy
visibility of fluorine-labeled methotrexate, 933

Farnesyl Transferase Inhibitors
against CML cell line

combining targeted agents (commentary), 225

cytoreductive effects, myeloma tumor cells, 563

SCH66336

with imatinib against BCR-ABL-positive cells, 219

-Fetoprotein Growth Inhibitory Peptides
cancer therapeutics (review), 1243

Fibroblast Activation Protein (FAP)
novel xenograft model for human FAP expression, 729

Fibrosarcoma Cells
HT-1080

in vitro cytotoxicity of fluorine-labeled methotrexate, 933

telomerase inhibition by siRNA, 209

triptolide derivative PG490-88, in vitro and xenograft model, solid tumors, 855

Flavopiridol
apoptosis induction

E2F1 and Mcl-1, lung cancer cells, 73

glioma cell lines, 139

with bryostatin, leukemia cells, 83

potentiates docetaxel-induced apoptosis

gastric cancer cells, in vitro and mouse xenografts, 549

3'-Fluoromethotrexate (FMTX)
synthesis and characterization, 933

5-Fluorouracil
with SU11248, breast cancer xenografts, 1011

Focal Adhesion Kinase (FAK)
phosphorylation

cisplatin resistance, squamous cell carcinoma cell line, 1207

SFK-dependent in tumor cells, 461

Formaldehyde
prodrug AN-9

Adriamycin-DNA adduct formation, sequence specificity, 661

prodrug HMTA

Adriamycin activation, 189

Fusion Proteins
glioma sensitivity

EGFR, IL-4, IL-13, and transferrin receptor expression, 783

G

G₁ Cell Cycle Arrest
by naamidine A, epidermoid cancer cells, 747

G3139 (Oblimersen)
mechanism of action in prostate cancer cells, 1031

Gastric Cancer
monoclonal antibody against, mAb MG7

identification of mimic epitopes with phage display technology, 301

Gastric Cancer Cells
MGC80-3

antitumor effects of triptolide, 65

MKN1, MKN28, MKN45

novel oncolytic adenovirus OV798, 1003

MKN-74

flavopiridol potentiates docetaxel-induced apoptosis, in vitro and mouse xenografts, 549

N87

in situ allicin generation with targeted alliinase delivery, 1295

Gastrointestinal Stromal Tumors
cell line GIST882

markers of response to Gleevec (imatinib mesylate), 699

Geldanamycin
derivative 17AAG

pharmacological audit trail (commentary), 131

physicochemical characteristics and Hsp90 binding affinity, prostate epithelial cells, 123

Gemcitabine
with LAQ824, breast cancer cells, 971

Gene Expression
GrB/VEGF₁₂₁, a novel vascular-targeting fusion construct, 949

identification with noninvasive imaging techniques (minireview), 335

MDA-7 iNOS expression, melanoma cells, 9

unsupervised self-organizing map analysis

cancer classification, 317

Gene Expression Profile
classification of synthetic retinoids and retinoid synergists, 49

Gleevec, gastrointestinal stromal tumor cells, 699

known and novel BCR/ABL activated genes, chronic myelogenous leukemia cells, 173

pediatric acute lymphoblastic leukemia cell lines, 671

relevance network with chemosensitivity, human hepatoma cells, 199

three HDAC inhibitors, bladder and breast cancer cell lines, 151

Gene-Directed Enzyme Prodrug Therapy
sensitization of osteosarcoma to CPT-11, 765

Genistein
with CHOP chemotherapy, large cell lymphoma xenografts, 1361

Gleevec (imatinib mesylate)
gene expression patterns and signaling pathways affected, gastrointestinal stromal tumor cells, 699

Glioblastoma Cells
M059K, U-87MG

glioma-endothelial coculture model to study laminin-8, 985

U118MG

novel oncolytic adenovirus OV798, 1003

U251MG

chemopotentiating ability of CEP-6800, mouse xenografts, 371

Glioblastoma Multiforme
flavopiridol-induced apoptosis, 139

Glioma Cells
A172, CCF-STTG1, T98G, U87MG, U118MG, U251MG, U373MG

flavopiridol-induced apoptosis, 139

SF767

MGMT-P140K-transduced hematopoietic cells allow BG/BCNU dose intensification, murine model, 1321

Gliomas
fusion protein therapy

receptor density measurements, 783

invasion reduced by inhibition of laminin-8

Morpholino, 985

molecular profiles for RG2 rat glioma cells, 1129

Glutathione
green fluorescent protein transduction, neuroblastoma cells, 911

Glutathione/glutathione S-transferase-activated Nitric Oxide Donor
JS-K

novel antineoplastic agent, 409

Glycogen Synthase Kinase-3ß Suppression
TRAIL-induced apoptosis, prostate cancer cells, 1215

G-quadruplex-intercalating Agents
tetra(N-methyl-4-pyridyl)-porphyrin chloride (TMPyP4)

telomerase inhibition and cell growth arrest, myeloma cells, 825

Green Fluorescent Protein
chemical synthetic lethality screen, mouse embryonal fibroblasts, 1121

increases oxidative stress and enhances drug sensitivity, neuroblastoma cells, 911

H

-H2AX
intranuclear focalization

adozelesin-induced, 41

Head and Neck Cancer Cells
squamous cell HSC-2

cisplatin resistance, 1207

Heat Shock Protein
abrogation of induction

intracellular acidification, melanoma cells, 383

Heat Shock Protein 90 (Hsp90)
and geldanamycin derivative 17AAG

binding affinity, prostate epithelial cells, 123

pharmacological audit trail (commentary), 131

novel histone deacetylase inhibitor LAQ824, breast cancer cells, 971

Hepatocellular Carcinoma
effect of tyrosine kinase inhibitor ZD1839 (Iressa), mice, 557

Hepatocyte Growth Factor/Scatter Factor (HGF/SF) Receptor
identification and characterization of synthetic Met tyrosine kinase inhibitors, 1085

Hepatoma Cells
Hep3B, HepG2, HLE, HLF, Huh6, Huh7, PLC/PRF/5, SK-Hep1

relevance network between chemosensitivity and gene expression profile, 199

HepG2

antiproliferative activity of selected isothiocyanates, 1045

HER2
radiosensitization by trastuzumab, breast cancer cells, 1113

Her-2 Depletion
novel histone deacetylase inhibitor LAQ824, breast cancer cells, 971

Herbal Medicine
allilcin from garlic

in situ allicin generation with targeted alliinase delivery, 1295

curcumin and resveratrol

TRAIL-induced apoptosis, prostate cancer cells, 95

triptolide from Tripterygium wilfordii

broad antitumor effects, 65

derivative PG490-88, in vitro and xenograft model, 855

Herceptin (Trastuzumab)
radiosensitization, breast cancer cells, 1113

Hexamethylenetetramine (HMTA)
Adriamycin activation, cultured IMR-32 neuroblastoma cells, 189

HIF-1 Transcription Factor Complex
anti-angiogenic activity of human endostatin, prostate cancer cells, 845

Histone Deacetylase (HDAC) Inhibitors
CI-994, colon cancer cells, 401

gene expression profiling, bladder and breast cancer cell lines, 151

novel hydroxamic acid analogue, LAQ824

lowers Her-2 and induces apoptosis, breast cancer cells, 971

PXD101

antitumor activity in vitro and in mouse xenografts, 721

with TRAIL

apoptosis and mitochondrial damage, leukemia cells, 1273

Homology Modeling
aurora2 kinase, 283

identification and characterization of synthetic Met tyrosine kinase indolinone inhibitors, 1085

Human Telomerase Reverse Transcriptase (hTERT)
inhibition

rapamycin, endometrial cancer cells, 789

siRNA, human cancer cells, 209

VD₃ with 9-cis-retinoic acid, prostate cancer cells, 739

Hyaluronan (HA)
novel synthetic peptide inhibitor

to identify role of HA in melanoma growth and metastasis, mice, 295

1-(2-hydroxy-4-morpholin-4-yl-phenyl)-ethanone
novel DNA-dependent protein kinase inhibitor, colon cancer cells, 1257

-hydroxy--phenylamides
inhibit prostate cancer cell proliferation, 1149

Hydroxypropyl methacrylamide (HPMA)
novel CPT copolymer

antitumor activity against human tumor xenografts, mice, 29

Hyperthermia
sensitization of melanoma

strategies to decrease intracellular pH, 383

Hypoxia-inducible Factor-1 (HIF-1)
HIF-1 inhibition by Trx-1 inhibitors PX-12 and pleurotin, 235

I

Imaging
diffusion magnetic resonance imaging

detection of changes in tumor cellularity (minireview), 581

¹⁹F magnetic resonance spectroscopy

visibility of fluorine-labeled methotrexate, 933

functional magnetic resonance imaging

three-dimensional imaging of large volumes (minireview), 419

magnetic resonance spectroscopy

brain tumors (minireview), 497

near-infrared optical imaging

cancer proteases (minireview), 489

reporter genes

multiple platforms (minireview), 335

role in anticancer therapy (commentary), 333

time-lapse confocal microscopy

novel measurement approach, effects of Vinca alkaloids on centromere dynamics, 427

Imatinib
Gleevec

gastrointestinal stromal tumor cells, 699

resistance

overcoming by combining targeted agents (commentary), 225

with SCH66336

BCR-ABL-positive cells, 219

Indolequinones
mitomycin C

potentiated by P450, breast cancer cells, in vitro and xenograft model, 901

Indolinone Kinase Inhibitor
SU11248

activity against KIT, small cell lung cancer, mice, 471

Indolyloxazoline Derivative
A-289099

biological activity, 227

Indomethacin
stabilizes ß-catenin phosphorylation, colorectal cancer cells, 509

Inducible nitric oxide synthase (iNOS)
induction

inhibits transformation and tumor phenotype, mouse epidermal JB6 cells, 1285

regulation

MDA-7, 9

role in carcinogenesis, and selective inhibitors (minireview), 815

Trx-1 inhibitors PX-12 and pleurotin, 235

5ß1 Integrin
cisplatin resistance, squamous cell carcinoma cell line, 1207

Interferon (IFN-) Signaling Pathway
inhibition by dnSTAT2

novel in vitro model, 453

Interleukin (IL)
IL-4 cytotoxin

prostate carcinoma, xenograft models, 245

IL-4 receptors

expression on brain tumors and normal brain tissues for available fusion proteins, 783

IL-6 response

prevention by farnesyl transferase inhibitors, myeloma tumor cells, 563

IL-8 upregulation

dacarbazine

role in chemotherapeutic resistance of melanoma, 753

IL-13 receptors

expression on brain tumors and normal brain tissues for available fusion proteins, 783

Interleukin-24 (MDA-7)
interacts with free radicals to promote cell death, renal cancer cells, 623

Intestinal Cells
FHS74 NT

chemopotentiating ability of CEP-6800, mouse xenografts, 371

Intratumoral Injection
virus dissemination during

reduced with alginate solution, 1233

Ionizing radiation
with adenoviral-mediated p16 gene transfer, nasopharyngeal cancer cells, 961

Irinotecan
with CEP-6800

chemopotentiation, mouse xenografts, 371

Isothiocyanates (ITCs)
antiproliferative activity, multiple cancer cell lines, 1045

K

Kahalalide F
a novel marine-derived compound

mechanism of action, prostate and breast cancer cells, 863

KIT Inhibition
SU11248 alone and with cisplatin

small cell lung cancer, mice, 471

L

Laminin-8
inhibition with antisense oligonucleotide Morpholino

role in human tumor cell invasion, glioma cells, 985

LAQ824
a novel hydroxamic acid analogue histone deacetylase inhibitor

lowers Her-2 and induces apoptosis, breast cancer cells, 971

Lavendamycin
characterization of cytotoxic activities of novel analogues, 517

Lethality screens
synthetic

mouse embryonal fibroblasts, 1121

Leukemia
chronic myelogenous leukemia (CML)

BCR/ABL-mediated gene expression profile, 173

SCH66336 with imatinib against BCR-ABL-positive cells, 219

Leukemia Cells
Cem, K562, Molt 4, NB4

antineoplastic activity of bisperoxovanadium analogues, 1053

HL60

classification of retinoids by gene expression profiling, 49

flavopiridol-induced apoptosis, 139

JS-K as novel antineoplastic agent, 409

synthetic taxane-based reversal agents, 1195

HL-60, Jurkat, U937

TRAIL with histone deacetylase inhibitors, leukemia cells, 1273

HL-60, U937

apoptosis by bryostatin 1 and flavopiridol combination, 83

K562

antiestrogens and BCRP-mediated drug resistance, 105

K562 and NB4

amifostine effect on p53-mediated apoptosis, 893

pediatric ALL

gene expression profiles, 671

promyelocytic HL60/S

antiproliferative activity of selected isothiocyanates, 1045

Liver Cancer
SU(Z)12 upregulation in human tumors, 113

Liver Metastasis
effects of ER-37328

murine Colon 38 orthotopic transplantation model, 59

L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester (tripeptide J3)
antitumor activity

comparison with m-L-sarcolysin analogue P2, 1331

L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester (tripeptide P2)
antitumor activity

comparison with novel melphalan-containing tripeptide J3, 1331

Lung Cancer
small cell

SU11248 alone and with cisplatin, mice, 471

Lung Cancer Cells
A549

camptothecin HPMA copolymers, 29

cytotoxic activities of novel Lavendamycin analogues, 517

novel docetaxel analogue MAC-321, in vitro and in vivo, 873

SFK dependency of STAT3 and FAK phosphoepitopes, 461

CALU-3

PXD101, a novel HDAC inhibitor, 721

H1299

Chk1 small interfering RNA, 543

p53 and radiosensitivity, 1223

LL2

antineoplastic activity of bisperoxovanadium analogues, 1053

NCl-H23

telomerase inhibition by siRNA, 209

NCl-H82

SU11248 activity against KIT, mice, 471

NCl-H526

SU11248 activity against KIT, mice, 471

non-small

A549

discodermolide, 1303

exisulind-induced apoptosis and docetaxel treatment, rats, 479

A549, EKVX

antineoplastic activity of bisperoxovanadium analogues, 1053

Calu-6

chemopotentiating ability of CEP-6800, mouse xenografts, 371

H23

triptolide derivative PG490-88, in vitro and xenograft model, solid tumors, 855

H460

Dox and Taxol induced apoptosis, 641

H1299

flavopiridol, 73

WIL

PXD101, a novel HDAC inhibitor, 721

Lung Metastasis Model
role of hyaluronan, mice, 295

Lung Tumors
reduced by novel aerosolized Vitamin E analog, mice, 437

Lymphoma B Cells
Daudi, 2F7, Raji, Ramos

rituximab and paclitaxel, 1183

Lymphoma Cells
WSU-DLCL₂

CHOP chemotherapy with genistein, 1361

Lysophosphatidic Acid Acyltransferase ß
phosphatidic acid generated from

cofactor in signaling pathways, 1067

M

MAC-321
a novel docetaxel analogue

compared with paclitaxel and docetaxel, multiple tumor cell lines in vitro and in vivo, 873

Macrophage Inhibitory Cytokine-1 (MIC-1)
novel biomarker for activation of p53

in vitro and in vivo models, 1023

Magnetic Resonance Imaging (MRI)
diffusion

detection of changes in tumor cellularity (minireview), 581

functional

noninvasive three-dimensional imaging of large volumes (minireview), 419

Magnetic Resonance Spectroscopy
brain tumors (minireview), 497

Manganese Superoxide Dismutase (MnSOD)
tumor suppression, pancreatic cancer, 361

Mathematical Models
behavior of tumor-host interface, 919

to improve chemotherapy design (minireview), 1079

Matrix Metalloproteinase-9 (MMP-9)
effect of tyrosine kinase inhibitor ZD1839 (Iressa), hepatocellular carcinoma, mice, 557

Mcl-1
down-regulation

apoptosis by bryostatin 1 and flavopiridol combination, 83

flavopiridol-induced apoptosis, lung cancer cells, 73

MDA-7 (Interleukin-24)
interacts with free radicals to promote cell death

renal cancer cells, 623

MDM2 protein
flavopiridol-induced apoptosis, glioma cell lines, 139

Melanoma
metastatic disease

effects of Atorvastatin, 941

Melanoma Cells
A375, A375.S2

MDA-7 regulation of iNOS, 9

A375-M

novel class of recombinant antibodies to deliver GrB, 1341

B16-F10

role of hyaluronan in cell growth and metastasis, mice, 295

DB-1

strategies to decrease intracellular pH for heat shock survival, 383

G361

novel oncolytic adenovirus OV798, 1003

HS852

PXD101, a novel HDAC inhibitor, 721

M14

camptothecin HPMA copolymers, 29

SB-2 and MeWo

mechanisms of resistance to dacarbazine, 753

Melanoma Differentiation Association Gene-7 (MDA-7)
expression

iNOS expression, 9

Melphalan
novel tripeptide J3

comparison with m-L-sarcolysin analogue P2, multiple cell lines, 1331

Met Tyrosine Kinase
identification and characterization of synthetic indolinone inhibitors, 1085

Methotrexate
fluorine-labeled FMTX

synthesis and characterization, 933

Methoxyamine
potentiates BCNU antitumor effect, in vivo and in vitro colon cancer cells, 1061

Microarray analysis
binarization of data based on multiplicative model for expression up-regulation, 679

contrasted with mechanistic mathematical models (minireview), 1079

gene expression profiling

classification of synthetic retinoids and retinoid synergists, 49

pediatric acute lymphoblastic leukemia cell lines, 671

Gleevec

gastrointestinal stromal tumor cells, 699

human hepatoma cells

relevance network between chemosensitivity and gene expression profile, 199

unsupervised self-organizing map analysis

cancer classification, 317

Microtubule Dynamics
discodermolide, lung cancer cells, 1303

primary mechanism of mitotic block, Vinca alkaloids, 427

Mimic Epitopes
for gastric cancer-associated mAb MG7

isolated by phage display technology, 301

Mitochondria
RRM-induced apoptosis

Z-FA-fmk, 255

Mitogen-activated Protein Kinase (MAPK)
ARB inhibits cell proliferation, prostate cancer cells, in vivo and in vitro, 1139

Dox and Taxol induced apoptosis, NSCLC cells, 641

effect of naamidine A, epidermoid cancer cells, 747

effect of tyrosine kinase inhibitor ZD1839 (Iressa), squamous cancer cells, 345

Mitomycin C
potentiated by P450, breast cancer cells, in vitro and xenograft model, 901

Mitoxantrone Cytotoxicity
synthetic taxane-based reversal agents, 1195

Molecular Modeling
development of camptothecin prodrugs activated by specific carboxylesterases, 1171

Monocarboxylate Transporter Isoform 1 (MCT-1)
blocker CNCn

strategies to decrease intracellular pH, melanoma cells, 383

Monoclonal Antibodies
MG7

phage display technology to identify mimic epitopes, 301

Mouse Embryonal Fibroblasts
chemical synthetic lethality screen, 1121

Multidrug Resistance
colcemid and vinblastine

- and ß-tubulin alterations, 597

expression

polymorphisms, 5' upstream regulatory region, 1351

sensitization strategies

apoptosis manipulation (minireview), 805

Multidrug Resistance Protein (MRP-1)
cloning and characterization from cynomolgus monkey

comparison with human, 307

overexpression

synthetic taxane-based reversal agents, 1195

Myeloma cells
8226

synthetic taxane-based reversal agents, 1195

8226, ARD, ARH77, ARK, ARP, U266, HeLa

telomerase activity and telomere length, 825

8226/S, 8226/Dox40

antiproliferative activity of selected isothiocyanates, 1045

8226/S, MM1.S, U266

arsenic trioxide-induced cell death, 1155

ANBL-6

cytoreductive effects of farnesyl transferase inhibitors, 563

ARD, ARH77, U266

TMPyP4, telomerase inhibition and cell growth arrest, 825

N

Naamidine A
causes G₁ cell cycle arrest

epidermoid cancer cells, 747

N-acetyldinaline or CI-994 [4-(acetylamino)-N-(2-amino-phenyl) benzamide]
HDAC inhibition, colon cancer cells, 401

Nasopharyngeal Cancer Cells
CNE-1, CNE-2Z

differential sensitivity to adenoviral-mediated p16 gene transfer with ionizing radiation, 961

Near-infrared Optical Imaging
cancer proteases (minireview), 489

Neuroblastoma Cells
CHLA-20, CHLA-90, CHLA-171, SMS-SAN

green fluorescent protein transduction, 911

Nitric Oxide. See also Inducible Nitric Oxide
induction

inhibits transformation and tumor phenotype, mouse epidermal JB6 cells, 1285

prodrug JS-K

novel antineoplastic agent, 409

5-[N-methyl-N-(4-octadecyloxyphenyl)acetyl]amino-2-methylthiobenzoic acid (VGA1155)
novel antagonist of VEGF receptor binding

identification and characterization, 1105

Non-Hodgkin's Lymphoma B Cells
Daudi, 2F7, Raji, Ramos

rituximab and paclitaxel, 1183

Nuclear Factor Kappa Beta (NF-B)
CHOP chemotherapy with genistein, large cell lymphoma xenografts, 1361

O

O⁶-Benzylguanine (O⁶-BG)
enhancement of platinum-induced cytotoxicity, head and neck cancer cell lines, 633

with BCNU

MGMT-P140K-transduced hematopoietic cells allow dose intensification, murine model, 1321

with BCNU and methoxyamine

potentiates BCNU antitumor effect, in vivo and in vitro colon cancer cells, 1061

O⁶-Methylguanine DNA Methyltransferase (MGMT)
drug resistance

MGMT-P140K-transduced hematopoietic cells allow BG/BCNU dose intensification, murine model, 1321

Oblimersen (G3139)
mechanism of action in prostate cancer cells, 1031

Oligodeoxynucleotide
antisense p21

breast cancer, 773

Oligonucleotides
antisense

Morpholino inhibition of laminin-8, glioma cells, 985

phosphorothioate

mechanism of action of G3139, prostate cancer cells, 1031

Oligosaccharide
cisplatin resistance, squamous cell carcinoma cell line, 1207

Oncolytic Adenovirus OV798
targeted to CEA-producing cancer cells

identification and characterization, 1003

Oncosis
induction by Kahalalide F, prostate and breast cancer cells, 863

Osteosarcoma
gene-directed enzyme prodrug therapy

sensitization to CPT-11, 765

mRNA expression of E2F transcription factors, 535

Osteosarcoma Cells
CCL121

telomerase inhibition by siRNA, 209

Ovarian Cancer
drug resistant

novel agent Alchemix maintains potent cytotoxicity, in vitro and in mice, 607

Ovarian Cancer Cells
A2780

camptothecin HPMA copolymers, 29

PXD101, a novel HDAC inhibitor, 721

PA-1

novel oncolytic adenovirus OV798, 1003

SKOV3TP5

SFK dependency of STAT3 and FAK phosphoepitopes, 461

Ovarian Sarcoma Tumors
regression after oral A-289099, mice, 227

Oxaliplatin
p53-independent response, mouse salivary tumors, 165

Oxidative Stress
induced by green fluorescent protein, neuroblastoma cells, 911

induction by arsenic trioxide

apoptosis in normal T cells, 711

P

p16
adenoviral-mediated gene transfer

with ionizing radiation, nasopharyngeal cancer cells, 961

p21
antisense oligodeoxynucleotide

breast cancer, 773

p53
activation in lung cancer cells

novel Lavendamycin analogues, 517

adenovirus-mediated

differential effects on radiosensitivity, epidermal and lung cancer cells, 1223

apoptosis mediated by

effect of amifostine, leukemia cells, 893

green fluorescent protein transduction, neuroblastoma cells, 911

pathway activation

novel biomarker MIC-1, in vitro and in vivo models, 1023

response to cisplatin and oxaliplatin, mouse salivary tumors, 165

P140 Mutant of MGMT (MGMT-P140K)
bone marrow transplantation allows BG/BCNU dose intensification, murine model, 1321

P450 Reductase
overexpression

mitomycin C sensitivity, breast cancer cells, in vitro and xenograft model, 901

Paclitaxel (Taxol)
comparison with novel docetaxel analogue MAC-321

multiple tumor cell lines in vitro and in vivo, 873

enhanced sensitivity to

- and ß-tubulin alterations, 597

induced apoptosis, NSCLS cells, 641

microtubule dynamics

compared with discodermolide, lung cancer cells, 1303

with rituximab, non-Hodgkin's lymphoma B cells, 1183

p21-Activated Kinase 1 (Pak1)
effect of tyrosine kinase inhibitor ZD1839 (Iressa)

squamous cancer cells, 345

Pancreatic Cancer
angiogenesis and growth

regulation by COX-2, 1

Pancreatic Cancer Cells
AsPC-1 and BxPC-3

COX-2 and angiogenesis, 1

CAPAN 1

camptothecin HPMA copolymers, 29

MIA PaCa-2

tumor suppression with MnSOD, 361

2,2,5,7,8-Pentamethyl-6-chromanol (PMCol)
androgen receptor antogonist activity, prostate cancer cells, 797

Peptichemio (PTC)
tripeptide P2 compared with novel tripeptide J3, multiple cells lines, 1331

Perifosine
a bioavailable alkylphospholipid

inhibits protein kinase B/Akt phosphorylation and activation, prostate cancer cells, 1093

PG490-88
solid tumor regression and chemosensitization, in vitro and xenograft model, 855

P-glycoprotein (Pgp)
expression

SNPs at 5[prime] regulatory region of human MDR1 gene, 1351

overexpression

synthetic taxane-based reversal agents, 1195

P-glycoprotein-mediated Resistance
overcome by novel docetaxel analogue MAC-321

multiple tumor cell lines in vitro and in vivo, 873

pH
intracellular

melanoma cell survival during heat shock, 383

Phage Display Technology
identification of mimic epitopes

for gastric cancer-associated mAb MG7, 301

molecular profiles for RG2 rat glioma cells, 1129

Phage Probes
molecular profiles for RG2 rat glioma cells, 1129

Pharmacological Audit Trail
Hsp90 molecular chaperone inhibitors

17AAG (commentary), 131

pH-dependent
formaldehyde-releasing prodrug HMTA

Adriamycin activation, 189

Phosphatase Inhibitors
bisperoxovanadium analogues

antineoplastic activity in vivo and in vitro, multiple cell lines, 1053

Phosphatidic Acid
derived from lysophosphatidic acid acyltransferase [beta]

cofactor in signaling pathways, 1067

Phosphatidylinositol 3-kinase (PI-3K)/Akt Pathway
and radiotherapy resistance

breast cancer cells, 353

Phosphoproteome
anticancer drug action

growth factor signaling, 1369

Phosphorothioate Oligonucleotides
mechanism of action in prostate cancer cells, 1031

Phycocyanin
apoptosis

rat AK-5 tumor line cells, 1165

Piroxicam
with cisplatin chemotherapy

urinary bladder cancer, canine model, 183

Plasmid-Based DNA Vaccine
encoding rat neu

alone or in combination with plasmids encoding CD80, CD86, CD137L, in mice, 995

Plasminogen Activator Inhibitor Type 1 (PAI-1)
mutants

novel cysteine mutations extend half-life, 19

Platinum-Based Chemotherapeutic Agents
cisplatin and oxaliplatin

p53 positive and negative MMTV-ras mice, 165

Platinum-Induced Cytotoxicity
enhancement by O⁶-BG, head and neck cancer cell lines, 633

Pleurotin
Trx-1 inhibitor

effect on HIF-1 and downstream targets, 235

Poly(ADP-ribose) Polymerase 1 (PARP-1) Inhibitor
CEP-6800

chemopotentiating ability, 371

Positron Emission Tomography (PET) Imaging
reporter genes

molecular imaging technology (minireview), 335

Prednisone
CHOP chemotherapy with genistein, large cell lymphoma xenografts, 1361

Prostaglandin E₂
piroxicam with cisplatin chemotherapy

urinary bladder cancer, canine model, 183

Prostate
epithelial cells

17AAG characteristics and Hsp90 binding affinity, 123

Prostate Cancer Cells
derivatives LNCaP-Pro5 and PC3M-Pro4

bortezomib, in vitro and in xenografts, 835

DU145

camptothecin HPMA copolymers, 29

IL-4 cytotoxin, xenograft models, 245

DU145, LNCaP, PC3

ARB inhibits cell proliferation, in vivo and in vitro, 1139

glycogen synthase kinase-3ß suppression and TRAIL-induced apoptosis, 1215

mechanism of action of Kahalalide F, 863

LAPC4, LNCaP

androgen receptor antogonist activity by vitamin E derivative, 797

LNCaP

apoptosis by TRAIL and curcumin combination, 95

DPI analogues prevent Akt translocation, 389

IL-4 cytotoxin, xenograft models, 245

in vivo MR visibility of fluorine-labeled methotrexate, mouse xenograft, 933

LNCaP, PC3

VD₃ with 9-cis-retinoic acid, hTERT transcription, 739

PC3

anti-angiogenic activity of human endostatin, 845

mechanism of action of G3139, 1031

perifosine inhibits protein kinase B/Akt phosphorylation and activation, 1093

PXD101, a novel HDAC inhibitor, 721

voltage-gated sodium channel blockers as inhibitors, 1149

Proteases
cancer

near-infrared optical imaging (minireview), 489

Proteasome
sulindac metabolite induction of [beta]-catenin protein degradation, colon cancer cells, 885

Protein Kinase B. See Akt
Protein Kinase B Activation   inhibited by perifosine, prostate cancer cells, 1093

Protein Kinase C (PKC)
activator bryostatin 1

apoptosis induction, leukemia cells, 83

inhibitor GFX

apoptosis induction, leukemia cells, 83

PKC

prosurvival factor in breast tumor cells, 273

Protein Kinase Inhibitors
novel DNA-dependent, colon cancer cells, 1257

Protein Kinases
Dox and Taxol induced apoptosis, NSCLC cells, 641

Protein Tyrosine Phosphatase Inhibitors
bisperoxovanadium analogues

antineoplastic activity in vivo and in vitro, multiple cell lines, 1053

PX-12
Trx-1 inhibitor

effect on HIF-1[alpha] and downstream targets, 235

PXD101
novel histone deacetylase inhibitor

antitumor activity in vitro and in mouse xenografts, 721

Pyrrole-indolinone
identification and characterization of synthetic Met tyrosine kinase inhibitors, 1085

Q

Quantization
gene microarray data

binarization based on multiplicative model for expression up-regulation, 679

R

Radioresistance
differential effects of p53, epidermal and lung cancer cells, 1223

Radiosensitization
breast cancer cells

trastuzumab, 1113

Rapamycin
telomerase inhibitor, endometrial cancer cells, 789

Receptor Tyrosine Kinase KIT Inhibition
SU11248 alone and with cisplatin, small cell lung cancer, mice, 471

Recombinant Antibodies
novel class

delivery of GrB, melanoma cells, 1341

Rectum Cancer Cells
SW1463

novel oncolytic adenovirus OV798, 1003

Reduced Folate Carrier (RFC)
mRNA expression of E2F transcription factors

osteosarcoma, 535

Relevance Network
chemosensitivity and gene expression profile

human hepatoma cells, 199

Remission
IL-4 cytotoxin, prostate cancer xenograft models, 245

Renal Cancer Cells
A498 and UOK121N

MDA-7 interacts with free radicals to promote cell death, 623

Renal Epithelial Cells
chemopotentiating ability of CEP-6800, mouse xenografts, 371

Replication Fork
progression

DNA damage-induced RPA hyperphosphorylation, 41

Replication Protein A (RPA)
hyperphosphorylation

DNA damage-induced, in S phase cells, 41

Reporter Genes
molecular imaging technology (minireview), 335

Resveratrol
apoptosis induction

with TRAIL, prostate cancer cells, 95

Retinoid Synergists
Am80 activity modulation

HL60 cells, 49

Retinoid-related Molecules (RRMs)
apoptosis

Z-FA-fmk, 255

Retinoids
classification

by gene expression profiling, 49

Rho Proteins
RhoC

effect of Atorvastatin, melanoma cells, 941

Rituximab (anti-CD20)
with paclitaxel, non-Hodgkin's lymphoma B cells, 1183

RNA Interference
short-interfering siRNA

inhibition of telomerase, human cancer cells, 209

to advance anticancer drug development (commentary), 217

ROS Generation
phycocyanin-mediated apoptosis in rat AK-5 tumor cells, 1165

S

S Phase Cells
DNA damage-induced RPA hyperphosphorylation, 41

Salivary Tumors
response to cisplatin and oxaliplatin

p53 positive and negative MMTV-ras mice, 165

Serine Protease Granzyme B (GrB)
Grb/VEGF₁₂₁, a novel vascular-targeting fusion construct

characterization and biological activities, 949

novel class of recombinant antibodies, melanoma cells, 1341

Serine/Threonine (S/T) Kinases
aurora kinases

homology modeling and docking simulations, 283

Signal Transducer and Activator of Transcription 2 (STAT2)
IFN- signaling suppression

novel in vitro model, 453

Signal Transducer and Activator of Transcription 3 (STAT3)
ARB inhibits cell proliferation, prostate cancer cells in vivo and in vitro, 1139

SFK-dependent in tumor cells, 461

upregulation and phosphorylation, MDA-7-treated melanoma cells, 9

Single Nucleotide Polymorphism (SNP)
identification of six new

MDR1 5' upstream regulatory region, 1351

Skin Cancer
effect of tyrosine kinase inhibitor ZD1839 (Iressa), 345

IFN- signaling suppression with dnSTAT2

novel in vitro model, 453

role of TNF-, mice, 445

Sodium Channel Blockers
-hydroxy--phenylamides

inhibit prostate cancer cell proliferation, 1149

Squamous Cancer Cells
Colo16, HaCaT, SRB1, SRB12

effect of tyrosine kinase inhibitor ZD1839 (Iressa), 345

HSC-2

cisplatin resistance, 1207

Src Family Kinases (SFKs)
STAT3 and FAK phosphorylation

tumor cell growth, 461

SU5416
a VEGF tyrosine kinase small molecule inhibitor

role in angiogenesis and prostate cancer, mice, 611

SU11248
a tyrosine kinase inhibitor

alone and with docetaxel, 5-fluorouracil, or doxorubicin, in breast cancer xenografts, 1011

SU11333
inhibitor of STAT3 and FAK phosphorylation

in vivo tumors, 461

Sulindac
induction of ß-catenin protein degradation, colon cancer cells, 885

SU(Z)12
promoter region analysis, 113

Synthetic Inhibitors
novel peptide inhibitor of hyaluronan

to identify role of HA in melanoma growth and metastasis, mice, 295

T

T Cell Factor (TCF)
TCF/ß-catenin complexes

SU(Z)12 upregulation in human tumors, 113

T Cells
CD4+ and CD8+

arsenic trioxide-induced apoptosis, 711

Tamoxifen
derivatives

BCRP-mediated drug resistance, 105

Taxanes
paclitaxel and docetaxel

compared with novel docetaxel analogue MAC-321, multiple tumor cell lines in vitro and in vivo, 873

synthetic taxane-based reversal agents

overexpression of Pgp, MRP-1, and BCRP, 1195

Taxol (Paclitaxel)
induced apoptosis, NSCLS cells, 641

Taxotere
with LAQ824, breast cancer cells, 971

Telomerase
activity and telomere length, myeloma cells, 825

hTERT transcription inhibition

VD₃ with 9-cis-retinoic acid, prostate cancer cells, 739

inhibition

rapamycin, endometrial cancer cells, 789

siRNA, human cancer cells, 209

TMPyP4, myeloma cells, 825

Temozolomide
with CEP-6800

chemopotentiation, mouse xenografts, 371

Tetra(N-methyl-4-pyridyl)-porphyrin chloride (TMPyP4)
telomerase inhibition and cell growth arrest, myeloma cells, 825

Tetrathiomolybdate
with doxorubicin

enhanced efficacy, breast cancer, mice, 617

Thioredoxin-1 (Trx-1) inhibitors
PX-12 and pleurotin

effect on HIF-1 and downstream targets, 235

Thymidylate Synthase
mRNA expression of E2F transcription factors

osteosarcoma, 535

Time-lapse Confocal Microscopy
novel measurement approach

effects of Vinca alkaloids on centromere dynamics, 427

T-lymphocyte Activation
identification with noninvasive imaging techniques (minireview), 335

TMPyP4 [tetra(N-methyl-4-pyridyl)-porphyrin chloride]

telomerase inhibition and cell growth arrest, myeloma cells, 825

TNF-induced nitric oxide production
inhibits transformation and tumor phenotype, mouse epidermal JB6 cells, 1285

-Tocopherol (Vitamin E)
antioxidant moiety 2,2,5,7,8-pentamethyl-6-chromanol

androgen antagonist activity, prostate cancer cells, 797

Transcriptional Regulatory Elements
carcinoembryonic antigen (CEA)

identification and characterization of oncolytic adenovirus OV798, a novel CEA promoter and enhancer, colorectal cancer, 1003

Transferrin Receptor
expression on brain tumors and normal brain tissues for available fusion proteins, 783

Trastuzumab (Herceptin)
radiosensitization, breast cancer cells, 1113

with LAQ824, breast cancer cells, 971

Tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester)
antitumor activity

comparison with m-L-sarcolysin analogue P2, 1331

Tripeptide P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester)
antitumor activity

comparison with novel melphalan-containing tripeptide J3, 1331

Triptolide
solid tumors

broad antitumor effects, 65

Triptolide Derivative PG490-88
solid tumor regression and chemosensitization, in vitro and xenograft model, 855

-Tubulin
mutations

role in resistance to Colcemid and vinblastine, 597

ß-Tubulin
mutations

role in resistance to Colcemid and vinblastine, 597

Tubulin Binding
indolyloxazoline derivative A-289099, 227

Tumor Necrosis Factor- (TNF-)
glycogen synthase kinase-3ß suppression and TRAIL-induced apoptosis, prostate cancer cells, 1215

increased release

apoptosis by bryostatin 1 and flavopiridol combination, leukemia cells, 83

promoter in experimental skin tumors, mice, 445

Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)
apoptosis induction

glycogen synthase kinase-3ß suppression, prostate cancer cells, 1215

with curcumin, prostate cancer cells, 95

with histone deacetylase inhibitors

apoptosis and mitochondrial damage, leukemia cells, 1273

Tumor Response
piroxicam with cisplatin chemotherapy

urinary bladder cancer, canine model, 183

Tumor Therapeutic Strategies
mathematical models of tumor-host interface, 919

Tumors. See also Xenograft Models
antitumor effects

17AAG concentrations, 123

chemosensitization strategies

apoptosis manipulation (minireview), 805

classification

gene expression microarray data, patient database, 317

colon, breast, liver

SU(Z)12 upregulation (humans), 113

growth

broad antitumor effects of triptolide, solid tumors, 65

effect of indolyloxazoline derivative A-289099, 227

inhibited by tyrosine kinase inhibitor ZD1839 (Iressa), murine hepatocellular carcinoma, 557

JS-K as novel antineoplastic agent, leukemia, 409

regulation by COX-2, pancreatic cancer, 1

suppression with MnSOD, pancreatic cancer cells, 361

mechanisms to resist apoptosis

and clinical approaches to induce apoptosis (minireview), 573

response to cisplatin and oxaliplatin

p53 positive and negative MMTV-ras mice, 165

role of iNOS in early development (minireview), 815

Tyrosine Kinase Inhibitor
ARB inhibits cell proliferation, prostate cancer cells in vivo and in vitro, 1139

emodin

with celecoxib, cultured rat cells, 265

imatinib

with SCH66336 against BCR-ABL-positive cells, 219

SU11248

alone and with docetaxel, 5-fluorouracil, or doxorubicin

breast cancer xenografts, 1011

ZD1839 (Iressa)

effect on EGFR, MAPK, and Pak1 activity, squamous cancer cells, 345

effect on metastatic properties of hepatocellular carcinoma, mice, 557

U

Urinary Bladder Cancer
piroxicam with cisplatin chemotherapy, canine model, 183

Urokinase (uPA)
inhibitors

novel PAI-1 cysteine mutations, 19

V

Vaccines
plasmid-based encoding rat neu

alone or in combination with plasmids encoding CD80, CD86, CD137L, in mice, 995

Vascular Endothelial Growth Factor (VEGF)
anti-angiogenic activity of human endostatin, prostate cancer cells, 845

expression

E1A gene therapy suppression, Ewing's sarcoma mouse xenografts, 1313

GrB/VEGF₁₂₁, a novel vascular-targeting fusion construct

characterization and biological activities, 949

receptor binding

identification and characterization of a novel inhibitor, VGA1155, 1105

signaling

role of SFK activity, 461

Trx-1 inhibitors PX-12 and pleurotin, 235

upregulation by dacarbazine

role in chemotherapeutic resistance of melanoma, 753

VD₃ (1,25-dihydroxyvitamin D₃)
with 9-cis-retinoic acid

hTERT transcription, prostate cancer cells, 739

Vegetables
isothiocyanates

antiproliferative activity, multiple cancer cell lines, 1045

VEGF Tyrosine Kinase
small molecule inhibitor SU5416

role in angiogenesis and prostate cancer, mice, 611

VGA1155
novel antagonist of VEGF receptor binding

identification and characterization, 1105

Vinblastine
mitosis blockade

suppression of spindle microtubule dynamics, 427

resistance

role of - and ß-tubulin alterations, 597

Vinca Alkaloids
mitosis blockade

suppression of spindle microtubule dynamics, 427

Vincristine
CHOP chemotherapy with genistein, large cell lymphoma xenografts, 1361

Vinflunine
mitosis blockade

suppression of spindle microtubule dynamics, 427

Vinorelbine
mitosis blockade

suppression of spindle microtubule dynamics, 427

Viral Vectors
dissemination during intratumoral injection

reduced with alginate solution, 1233

Virus Dissemination
during intratumoral injection

reduced with alginate solution, 1233

Vitamin E (-tocopherol)
antioxidant moiety 2,2,5,7,8-pentamethyl-6-chromanol

androgen antagonist activity, prostate cancer cells, 797

novel aerosolized analog -TEA

decreases tumor burden and metastasis, mice, 437

Voltage-gated Sodium Channel Blockers
-hydroxy--phenylamides

inhibit prostate cancer cell proliferation, 1149

X

Xenograft Models
breast cancer

P450 potentiates mitomycin C, 901

SU11248 alone and with docetaxel, 5-fluorouracil, or doxorubicin, 1011

colon cancer

BCNU antitumor effect, 1061

novel DNA-dependent protein kinase inhibitors, 1257

novel oncolytic adenovirus OV798, 1003

p53 activation biomarker MIC-1, 1023

SFK dependency of STAT3 and FAK phosphoepitopes, 461

Ewing's sarcoma

E1A gene therapy, 1313

gastric cancer

docetaxel followed by flavopiridol, 549

in situ allicin generation with targeted alliinase delivery, 1295

glioma

MGMT-P140K-transduced hematopoietic cells allow BG/BCNU dose intensification, 1321

large cell lymphoma

CHOP chemotherapy with genistein, 1361

multiple cell lines

antitumor effects of triptolide, 65

camptothecin HPMA copolymers, 29

CEP-6800, 371

5F-203 induction of CYP1A1, 1265

novel docetaxel analogue MAC-321, 873

PXD101, a novel HDAC inhibitor, 721

nasopharyngeal cancer

adenoviral-mediated p16 gene transfer with ionizing radiation, 961

novel human skin/SCID mouse chimeric model

human FAP expression, 729

osteosarcoma

Ad-sCE2 and CPT-11 sensitization, 765

prostate cancer

ARB inhibits cell proliferation, in vivo and in vitro, 1139

bortezomib, 835

IL-4 cytotoxin, 245

in vivo MR visibility of fluorine-labeled methotrexate, 933

VD₃ with 9-cis-retinoic acid, 739

solid tumors

triptolide derivative PG490-88 with CPT-11, 855

X-linked Inhibitor of Apoptosis (XIAP)
protein expression

Dox and Taxol induced apoptosis, NSCLC cells, 641

Z

Z-FA-fmk
inhibition of recombinant caspases, 255

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content